Coronary artery constriction by the isoprostane 8-epi prostaglandin F(2α)

British Journal of Pharmacology

Volumn 119, Issue 6, 1996, Pages 1276-1280

  Kromer, Brendan M ^a   Tippins, John R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Coronary artery disease; Ischaemia; Isoprostane; Oxidant stress

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 8 ISOPROSTAGLANDIN F2 ALPHA; DALTROBAN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CATTLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; NONHUMAN; PRIORITY JOURNAL; SHEEP; SPECIES DIFFERENCE; SWINE; VASOCONSTRICTION;

EID: 0029959421     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb16033.x     Document Type: Article

References (23)

1. AUSTEN, W.G., EDWARDS, J.E., FRYE, R.L., GENSINI, G.G., GOTT, V.L., GRIFFITH, L.S., MCGOON, D.C., MURPHY, M.L. & ROE, B.B. (1975). A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation, 51, (Suppl.), 5-40.
2. BANERJEE, M., KANG, K.H., MORROW, J.D., ROBERTS, L.J. & NEWMAN, J.H. (1992). Effects of a novel prostaglandin, 8-epi-PGF2 alpha, in rabbit lung in situ. Am. J. Phvsiol., 263, H660-H663.
3. CHANDRA, M., CHANDRA, N., AGRAWAL, R., KUMAR, A. GHATAK, A. & PANDEY, V.C. (1994). The free radical system in ischemic heart disease. Int. J. Cardiol., 43, 121-125.
4. DUBOIS RANDE, J.L., ARTIGOU, J.Y., DARMON, J.Y., HABBAL, R., MANUEL, C., TAYARANI, I., CASTAIGNE, A. & GROSGOGEAT, Y. (1994). Oxidative stress in patients with unstable angina. Eur. Heart J., 15, 179-183.
5. FUKUNAGA, M., MAKITA, N., ROBERTS, L.J.D., MORROW, J.D., TAKAHASHI, K. & BADR, K.F. (1993). Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol., 264, C1619-C1624.
6. HALUSHKA, P.V., ALLAN, C.J. & DAVISBRUNO, K.L. (1995). Thromboxane A2 receptors. J. Lipid Med. Cell Sig., 12, 361-378.
7. HENNIG, B. & CHOW, C.K. (1988). Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Radic. Biol. Med., 4, 99-106.
8. HIRATA, M., HAYASHI, Y., USHIKUBI, F., YOKOTA, Y., KAGEYAMA, R., NAKANISHI, S. & NARUMIYA, S. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349, 617-620.
9. JAYAKUMARI, N., AMBIKAKUMARI, V., BALAKRISHNAN, K.G. & IYER, K.S. (1992). Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis, 94, 183-190.
10. KENAKIN, T. (1993). Pharmacologie Analysis of Drug-Receptor Interaction. pp. 315-318. New York: Raven Press.
11. 2α, an F2 isoprostane, on porcine and ovine coronary arteries in vitro. Br. J. Pharmacol., 116, 285P.
12. 2α in porcine and coronary artery are inhibited by thromboxane receptor antagonists. Br. J. Pharmacol., 118, 87P.
13. 2, on the platelet thromboxane/ endoperoxide receptor in humans and rats: additional evidence for the existence of a unique isoprostane receptor. Prostaglandins, 48, 247-256.
14. MORROW, J.D., HILL, K.E., BURK, R.F., NAMMOUR, T.M., BADR, K.F. & ROBERTS, L.J.D. (1990). A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U.S.A., 87, 9383-9387.
15. MORROW, J.D., MINTON, T.A. BADR, K.F. & ROBERTS, L.J.N. (1994a). Evidence that the F2-isoprostane, 8-epi-prostaglandin F2 alpha, is formed in vivo. Biochim. Biophys. Acta, 1210, 244-248.
16. MORROW, J.D., MINTON, T.A., MUKUNDAN, CR., CAMPBELL, M.D., ZACKERT, W.E., DANIEL, V.C., BADR, K.F., BLAIR, I.A. & ROBERTS, L.J.N. (1994b). Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J. Biol. Chem., 269, 4317-4326.
17. MORROW, J.D., MINTON, T.A. & ROBERTS, L.J.D. (1992). The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins, 44, 155-163.
18. MORROW, J.D., MOORE, K.P., AWAD, J.A., RAVENSCRAFT, M.D., MARINI, G., BADR, K.F., WILLIAMS, R. & ROBERTS, L.J.D. (1993). Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. J. Lipid Mediat., 6, 417-420.
19. MORROW, J.D. & ROBERTS, L.J. (1996). The isoprostanes - current knowledge and directions for future research. Biochem. Pharmacol., 51, 1-9.
20. MULVANY, M.J. & HALPERN, W. (1977). Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res., 41, 19-26.
21. OGLETREE, M.L., HARRIS, D.N., GREENBERG, R., HASLANGER, M.F. & NAKANE, M. (1985). Pharmacological actions of SQ29548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther., 234, 435-441.
22. ROBERTS, L.J.N. & MORROW, J.D. (1994). Isoprostanes. Novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann. New York Acad. Sci. U.S.A., 744, 237-242.
23. STRINGER, M.D., GOROG, P.G., FREEMAN, A. & KAKKAR, V.V. (1989). Lipid peroxides and atherosclerosis. Br. Med. J., 298, 281-284.